Ab&B Bio-Tech CO., LTD. JS (Stock Code: 2627) has issued a profit alert indicating an expected revenue of 446.00 million to 493.00 million renminbi for the year ended December 31, 2025, reflecting a year-on-year increase of approximately 71.8% to 89.9% compared to 259.60 million renminbi in 2024.

The net loss is projected to narrow to around 157.00 million to 197.00 million renminbi from 258.70 million renminbi in the previous year, representing a reduction of roughly 23.9% to 39.3%. The announcement attributes this performance primarily to enhanced quality management systems that reduced production costs, targeted digital marketing strategies that strengthened sales efficiency, and an expanded product distribution network covering more disease control centers and vaccination clinics.

The company notes that these figures are based on unaudited management accounts and remain subject to potential adjustments in the forthcoming annual results announcement, expected to be published at the end of March 2026.